m+Medelevator.RU
← Поиск публикаций
Orbit (Amsterdam, Netherlands) · 2026

Orbital lobe dacryoadenectomy for refractory epiphora: a retrospective case series.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Quaranta-Leoni Flavia, Bianchi Eduardo, Leonardi Antonella, Quaranta-Leoni Francesco M

Аннотация

PURPOSE: To evaluate epiphora and ocular surface outcomes after macroscopically complete orbital lobe dacryoadenectomy with palpebral lobe preservation in selected patients with refractory epiphora after failed or intolerable conjunctivodacryocystorhinostomy (CDCR).

METHODS: This retrospective single-center case series included 11 consecutive patients with proximal canalicular obstruction and persistent epiphora after Jones tube failure or intolerance. The primary outcome was change in Munk score at 6 months. Secondary outcomes included Schirmer I, tear film break-up time (TBUT), lower tear-meniscus height, ocular surface findings, satisfaction, reintervention and complications.

RESULTS: All 11 patients improved by at least two Munk grades; median Munk score decreased from 4 (interquartile range [IQR], 3.5-4.0) to 1 (IQR, 1-2; exact Wilcoxon p = .001). Mean Schirmer I decreased by 4.91 mm/5 min (95% confidence interval, 3.15-6.67; p < .001) and mean TBUT by 1.05 s (95% confidence interval, 0.63-1.46; p < .001). Eight patients (72.7%) were satisfied or very satisfied and 10 (90.9%) were at least moderately satisfied. No patient underwent further lacrimal intervention or met the defined documentation based ocular surface event.

CONCLUSIONS: In this highly selected series, macroscopically complete orbital lobe dacryoadenectomy with palpebral lobe preservation was associated with substantial improvement in refractory epiphora after failed or intolerable CDCR. Reduced Schirmer I and TBUT support cautious patient selection and longer prospective follow-up.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты